Crucell and DSM Announce PER.C6® Licensing Agreement with GlaxoSmithKline for Monoclonal Antibody Production

13-Aug-2004

Leiden/Sittard, The Netherlands. Dutch biotechnology company Crucell N.V. and allied contract manufacturer DSM Biologics announced that Crucell has signed a PER.C6® research license agreement with GlaxoSmithKline. This license allows GlaxoSmithKline to use Crucell's PER.C6® technology in research and preclinical development related to its portfolio of recombinant monoclonal antibody products.

Under the terms of the agreement, Crucell and DSM Biologics will receive an upfront payment and annual maintenance fees. Further financial details were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances